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Abstract: Recent advances in the development of new methods of cancer immunotherapy require 
the production of complex cancer animal models that reliably reflect the complexity of the tumor 
and its microenvironment. Mice are good animals to create tumor models because they are low cost, 
have a short reproductive cycle, exhibit high tumor growth rates, and can be easily genetically 
modified. However, the obvious problem of these models is the high failure rate observed in human 
clinical trials after promising results obtained in mouse models. In order to increase the reliability 
of the results obtained in mice, the tumor model should reflect the heterogeneity of the tumor, 
contain components of the tumor microenvironment, in particular immune cells, to which the action 
of immunotherapeutic drugs are directed. This review discusses the current immunocompetent and 
immunocompromised mouse models of human tumors that are used to evaluate the effectiveness 
of immunotherapeutic agents, in particular chimeric antigen receptor (CAR) T-cells and immune 
checkpoint inhibitors. 
Keywords: cancer mouse models; cancer immunotherapy; immune checkpoint inhibitors; CAR T-
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1. Introduction 
The tumor microenvironment (TME) consists of a large number of different normal cells that 
play an important role in the development and progression of the tumor [1]. Stromal fibroblasts, 
infiltrating immune cells, blood and lymphatic vessels, the extracellular matrix, as well as cytokines 
and growth factors secreted by TME cells, can contribute both positively and negatively to tumor 
development [2]. Immunotherapy targets the immune component of TME in order to enhance the 
antitumor immune response or overcome the ability of the tumor to avoid immunological 
surveillance [3]. Recent advances in understanding interactions between the tumor and the immune 
system have allowed the development of new immunotherapy. Approaches such as immune 
checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cells, aim to use the immune 
system to create effective antitumor responses [4,5]. ICIs are a new class of antitumor 
immunotherapeutic agents, which act as suppressors of many immune checkpoints, especially in 
cytotoxic T-cells [6]. Under normal conditions, immune checkpoints can suppress the excessive 
immune response activation, the development of autoimmune reactions and the damage of the 
body's own healthy tissue [7]. However, the expression of some immune checkpoint ligands on the 
tumor cell surface allows the tumor to suppress the antitumor immune response and to evade the 
immune surveillance [8]. ICIs can disrupt these inhibitory signals and restore T-cell cytotoxicity 
against tumor cells [9]. CAR T-cell-based therapy involves the genetic modification of a patient's 
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autologous T-cells to express CAR targeted at a tumor-specific antigen [10]. Expression of tumor-
specific TCR allows CAR T-cells to directly identify the tumor antigen independently of major 
histocompatibility complex (MHC) and overcome some of the main mechanisms by which tumors 
can prevent MHC-based detection by T-cells [11,12]. The binding of CAR T-cells with cancer cells 
stimulates T-cell activation, proliferation and cytotoxic effect against the tumor [13]. 
To evaluate the effectiveness of immunotherapy, animal models are required in which a human 
tumor and its microenvironment are genetically, physiologically and anatomically modeled so that 
the formation and development of the tumor in humans are reliably reflected. Mice are low in cost 
relative to other animal models, have a short reproductive cycle, exhibit high tumor growth rate, and 
can be easily genetically modified [14]. These advantages make mouse models a good tool to evaluate 
the effectiveness of immunotherapeutic approaches for the cancer treatment. However, the ability to 
translate encouraging results of immunotherapy from bench to clinic is challenging now because of 
the high failure rate observed in human clinical trials after promising results obtained in mouse 
models. This review discusses the current immunocompetent and immunocompromised mouse 
models of human tumors that are used to evaluate the effectiveness of immunotherapeutic agents, in 
particular CAR T-cells and immune checkpoint inhibitors. 
2. Syngeneic Tumor Models 
Transplantation of in vitro cultured tumor cells into immunocompetent mice is the oldest and 
most commonly utilized approach to investigate antitumor therapy, including immunotherapy 
(Figure 1A) [15]. Spontaneous, carcinogenic or transgenic tumor cell lines can be transplanted into 
such mouse strains as C57BL/6, BALB/c and FVB [16–20]. The creation of such models takes a short 
period of time, since transplanted subcutaneously or intravenously cells grow in the animal within a 
few weeks [21]. The fast kinetics of tumor growth in syngeneic models often provides an inadequate 
time interval for evaluating the effectiveness of immunotherapy, since usually the effect of 
immunomodulating treatment develops gradually and is estimated by increasing survival rate [15]. 
Also, in syngeneic models it is impossible to evaluate the effectiveness of immunotherapeutic drugs 
at earlier stages of the tumor development [22]. 
Undoubtedly, the formation of transplanted tumors is different from tumors originating de 
novo. Moreover, the tumor microenvironment will be mostly determined by the local innate immune 
response triggered by injection-induced inflammation and the presence of a large number of tumor 
cells [23,24]. Usually, tumor cells are injected subcutaneously, as it is easier to track tumor 
development [25]. In order to make TME closer to that of people, the tumor cells can be orthotopically 
transplanted into the corresponding organs [26], such as intravenous administration of leukemia and 
lymphoma cells [27], injection of breast tumor cell lines into mammary adipose tissue [28], 
intrapancreatic injection of pancreatic duct adenocarcinoma [29], and intracranial injection for 
glioblastoma cell lines [30,31]. These administration routes more accurately reflect TME, but require 
more complicated manipulations and special equipment for both the transplantation and monitoring 
of the further tumor development [32]. 
Besides the fact that TME may prove to be unnaturally homogeneous, the syngeneic model of 
the tumor also lacks genomic heterogeneity, which makes each tumor unique [14]. The absence of 
mutational heterogeneity in syngeneic tumors is partly due to the absence of cancer stem cells and 
other populations of progenitor cells that are presented in TME and provide a constant source of new 
mutations for tumor evolution [33]. In addition, cells intended for transplantation often undergo 
adaptation to harsh in vitro or in vivo conditions, which leads to a decrease in the heterogeneity of 
tumor cells [34]. 
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Figure 1. Production of mouse tumor models for evaluation of immunotherapy. (A) Syngeneic tumor 
models are produced by transplanting mouse tumor cell lines into immunocompetent animals in a 
short period of time. (B) In genetically engineered tumor models, the tumor forms de novo as a result 
of specific genome modification. (C) In mice treated with carcinogens, the tumor also forms 
spontaneously de novo. (D) For the production of patient-derived xenograft (PDX) models with 
human immune system immunocompromised mice can be humanized with peripheral blood 
mononuclear cells (PBMCs) or hematopoietic stem cells (HSCs), and after that transplanted with a 
human tumor. 
To study the effectiveness of CAR T-cell therapy in syngeneic models, mouse cell-derived CAR-
T-cells are used [35]. Mouse models allow the toxicity of CAR T-cells to be determined, which 
depends on both the dose and the presence of co-stimulatory domains in the chimeric receptor [36]. 
A syngeneic model of lymphoma in BALB/c mice originally showed that first-generation CAR T-cells 
(without co-stimulatory domains) killed lymphoma cells, but did not cause side effects [37]. In 
contrast, second generation CAR T-cells with CD28 co-stimulatory domain induced B-cell aplasia and 
chronic toxicity, accompanied with an increase in the number of suppressor cells. It is worth noting 
the toxicity described above has not been observed in lymphoma models created in C3H or C57BL/6 
mouse strains, which means the results vary depending on the mouse strain [38]. 
Syngeneic tumor models are also used to investigate the antitumor activity of ICIs, including 
anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) [39] and anti-programmed death (PD)-1 
anti-PD-L1 antibodies [31,40]. For example, using the syngeneic model of immunocompetent B6 mice 
transplanted with E.G7 hematopoietic cell line or its analogue with PD-L1 deficiency it has been 
shown that the PD-L1 pathway blockade contributed to the rejection of tumor cells in mice 
transplanted with both wild-type (WT) E.G7 cells or PD-L1 deficient E.G7 cells in the same degree. 
Thus, the expression of PD-L1 on the cells of TME (either tumor infiltrating leukocytes or stromal 
cells) may contribute more significantly than the expression of PD-L1 on tumor cells [41]. One of the 
significant drawbacks of using syngeneic models to evaluate the effectiveness of ICIs is that the rapid 
growth of the tumors in syngeneic mouse models does not contribute towards the development of 
the chronic inflammatory environment typical for human tumors. Whilst during tumor formation, 
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immunological inhibitory pathways associated with inflammation, such as the PD-1/PD-L1 axis, are 
activated, which contributes significantly to TME remodeling [42]. 
3. Genetically Engineered Mouse Models 
The next step in the development of mouse tumor models was the creation of the mice in which 
autochthonous tumors develop in specific tissue due to the inclusion of specific changes in the 
genome (Figure 1B). Genetically engineered mouse models (GEMMs) are usually produced using 
transgenic technologies to provide systemic or tissue-specific expression of oncogenes, such as KRAS 
and MYC in breast cancer [43] and/or deletion of cancer suppressor genes, such as PTEN and TP53 in 
prostate cancer [44]. These transgenic models can be further divided into germline GEMMs and non-
germline GEMMs [45]. Germline GEMMs have mutations that lead to the spontaneous development 
of malignant neoplasms. For example, it has been shown that in mice with a TP53 gene mutation, a 
wide range of solid and hematological malignancies develops [46]. Germline GEMMs have allowed 
the detailed study of the mechanisms of tumor formation and development, but it is very labor-
intensive and does not allow control over the moment and place of tumor onset [47]. Non-germline 
GEMMs, on the other hand, provide spatiotemporal control of the onset of transformation. Induction 
of somatic mutations at a selected time and in a specific tissue can be achieved using various systems, 
for example, the tamoxifen-inducible Cre-loxP system in which, after the endogenous activation of 
Cre-recombinase by tamoxifen, any gene flanked by loxP recombination sites is deleted [48]. Also, 
RNA interference (RNAi) using short hairpin RNAs (shRNAs) are used to create non-germline 
models. For example, shRNA-mediated suppression of adenomatous polyposis coli (APC) tumor 
suppressor in the presence of KRAS and TRP53 mutations induces the development of colon 
carcinomas that undergo stable regression after the restoration of APC expression by disabling 
shRNA expression [49]. The CRISPR/Cas9 technology has recently been actively used for somatic 
editing of oncogenes, due to which models of hepatocellular carcinoma [50], lung cancer [51], breast 
cancer [52] have been created. Although the CRISPR/Cas9 gene editing system is extremely efficient 
in vivo, somatic Cas9 delivery can trigger Cas9-specific immune responses, which will lead to the 
elimination of cells expressing Cas9 [53]. Moreover, CRISPR/Cas9-mediated genome editing can 
create unwanted mutations outside the target [54]. 
In general, de novo tumor formation provides organization of complex TME as well as allowing 
the tumor to undergo immune tolerance, immuno-editing and/or immunosuppressive processes [55]. 
Sequential tumor development is a critical advantage of GEMMs compared to syngeneic tumor 
models, making them especially important for evaluating immunotherapy methods. Also, the 
interaction of the tumor with the immune system leads to the formation of heterogeneity, which can 
be enhanced by affecting the genes associated with mismatch repair and genomic stability, such as 
MLH1 [56] and BRCA1/2 [57]. An increase in the mutational burden can lead to the formation of 
neoantigens that can be recognized by immune cells [58]. However, this can lead to the evolution of 
the anti-cancer immune response, which will affect the effectiveness of immunotherapy [59]. In view 
of this, the GEMMs phenotype is poorly reproducible in comparison with syngeneic models. Another 
challenge is the requirement for non-invasive imaging techniques, such as ultrasound or magnetic 
resonance imaging, to monitor tumor development and evaluate antitumor immune responses [60]. 
To study the effectiveness of CAR T-cells, genetically modified mice are infrequently-accessed 
compare to syngeneic or patient-derived xenograft models. Most often, mice are genetically modified 
to express human tumor associated antigen (TAA) transgenes (the mouse TAAs are knocked out) 
and the tumor is syngeneic [61]. Murine T-cells that express human TAA are used in these studies 
[62,63]. Since most TAAs are expressed not only in tumors, but also at lower levels in healthy tissues, 
transgenic mice serve as an important model for evaluating the undesirable side effects that are 
observed in CAR T-cell therapy [64]. For example, C57BL/6 mice were genetically modified to express 
human carcinoembryonic antigen (CEA), which is overexpressed in many cancers of the 
gastrointestinal and pulmonary tracts, but it is not tumor specific and is also expressed in healthy 
intestine and lung tissue. Transgenic mice were treated with anti-CEA CAR T-cells, which resulted 
in long term tumor eradication, but also led to the heavy infiltration of the intestines and lung with 
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anti-CEA CAR T-cells in the transgenic but not in WT mice. However, despite the strong infiltration 
of healthy tissues, autoimmune inflammatory responses were not observed [61]. 
In the field of ICIs, genetically modified models are also not often used. A pancreatic ductal 
adenocarcinoma model, created using Cre-Lox technology, which activates mutant endogenous 
alleles of the KRAS and TRP53 genes, has been described [65]. Unfortunately, anti-PD-1 antibody 
therapy did not lead to a significant effect on tumor growth in these mouse models [66]. 
4. Carcinogen-Induced Tumor Models 
Tumor formation in mice can also be induced by carcinogens (CI)(Figure 1C) [67,68]. Some of 
the well-studied CI models include methylcholanthrene (MCA)-induced fibrosarcomas [69], 
ultraviolet B-induced skin cancer [70], azoxymethane/dextran sodium sulfate-induced colon 
carcinoma [71], 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK) tobacco carcinogen-
induced lung cancer [72,73]. In addition, many carcinogens such as N-methyl-N-nitrosourea (MNU) 
are used to create mouse, rat and other mammalian models to investigate antitumor therapy 
(discussed in [74]). Genome instability caused by a mutagen allows for an induction of de novo tumor 
formation in the corresponding microenvironment [75]. CI tumor models require a long time to 
establish, however, they have great genome complexity, which accurately reflects the real neogenesis 
of tumors in humans. Moreover, due to the greater mutational burden, different levels of 
immunogenic neoantigens are potentially generated, which affects the immunogenicity of the tumor 
[76]. Due to the potentially large number of unknown neoantigens, it is difficult to control and 
evaluate the immune response in CI models; therefore, they are rarely used to evaluate the 
effectiveness of CAR T-cell therapy or ICIs. However, the mouse model of 4-nitroquinoline 1-oxide 
(4NQO)-induced premalignant oral lesions that progress to oral cancer has been used to evaluate the 
effectiveness of the anti-PD-1 antibody [77,78]. 
5. Human Xenograft Models 
The models described above allow the establishment of mouse tumors with a microenvironment 
consisting of mouse cells, which makes it possible to elaborately study the mechanisms of the tumor 
formation and their interactions with TME cells. However, to evaluate the effectiveness of 
immunotherapeutic approaches, models with human tumors that interact with cells of the human 
immune system are required, since the components of the mouse immune system do not always 
correspond to those in humans [79]. For this reason, a huge number of encouraging therapeutics, 
which showed promising results in mice in preclinical trials, were not able to show effectiveness in 
human trials [80]. Human xenograft models are immunocompromised hosts, into which human cells 
are transplanted. One of the oldest and most widespread animals for creating human xenografts is 
the athymic nude mice or severe combined immunodeficiency (SCID) mice, which are commonly 
used to evaluate the effectiveness of cytotoxic drugs [81]. Classic athymic nude mice have abnormal 
development of the thymus, which leads to severe T-cell dysfunction, however, they still have innate 
immune system components (neutrophils and dendritic cells (DCs), NK cells) and B cells [82]. SCID 
mice are deficient in DNA-dependent protein kinase, which is essential for the development of T- 
and B cells [83]. The engraftment efficiency of human tumors in SCID mice is higher than that 
compared to nude mice [84]. Also, SCID mice were the first to transplant human hematopoietic stem 
cells (HSCs) and peripheral blood mononuclear cells (PBMCs) [85,86]. However, the NK cell activity 
greatly limits the engraftment of human hematopoietic elements and other primary cells in such 
models; therefore, athymic nude or SCID mice are mainly used for the transplantation of human 
tumor cell lines [87]. However, it is worth noting that the engraftment rate of gastrointestinal tumors 
in nude mice is relatively high, while the engraftment of hematological malignancies is almost 
impossible [88]. Knockout of the Rag1 and Rag2, as well as the interleukin (IL2)rγ genes made it 
possible to create of NOD SCID gamma (NSG) mice with impaired functions of IL2, IL4, IL7, IL9, 
IL15, and IL21 receptors and the absence of NK cells that allows successful transplantation of the 
primary tumors and human immune components [89]. However, NSG models and other 
immunocompromised models are also actively used for transplantation of tumor cell lines [90]. For 
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example, CD19 CAR T-cell therapy controlled the progression of Raji B-cell lymphoma in the NSG 
model [91]. Adoptive transfer of glypican 3 (GPC3)-CAR T-cells suppressed growth of HepG2 and 
Huh-7 cell lines, which were subcutaneously transplanted in immunodeficient NOD/SCID/IL2rg−/− 
(NSI) mice [92]. 
5.1. Patient-Derived Xenograft Models 
Transplantation of primary patient tumors allows the creation of patient-derived xenograft 
models (PDX) that accurately reflect the complexity mediated by the natural development of the 
tumor, including genomic heterogeneity, tumor architecture and microenvironment factors, 
especially if the tumors are transplanted orthotopically [93,94]. PDX models of hematopoietic and 
lymphoid tissue tumors are actively used to evaluate and develop new CAR T-cell therapies aimed 
at various tumors [95,96]. The greatest success was achieved in the treatment of hematological 
tumors. For example, CAR T-cells targeting the thymic stromal lymphopoietin receptor (TSLPR) 
eliminated leukemia in 4 acute lymphoblastic leukemia xenograft models with overexpression of 
human cytokine receptor like factor 2 (CRLF2) [97]. The administration of human epidermal growth 
factor receptor 2 (HER2)-specific CAR T-cells led to regression or even elimination of the colorectal 
cancer xenograft and protection of relapse from rechallenged colon cancer tissue in the PDX model 
[95]. One of the promising areas that is being investigated in PDX models is the creation of CAR T-
cells, the activation of which depends on several antigens in order to minimize side effects on healthy 
tissues. For example, the use of bispecific CAR T-cells targeting CD19 and CD20 allowed killing 
mixed populations of CD19 leukemia cells in the NSG model [96]. 
However, in order to effectively evaluate other types of immunotherapy, in particular ICIs, it is 
necessary to reconstruct the immune system, ideally from the same patient from whom the tumor 
was obtained. HSCs can be used to reconstruct the immune system (Figure 1D), both autologous and 
allogeneic HSCs can be used, since the collection of HSCs from a cancer patient may be limited [98]. 
Transplanted CD34+ HSCs develop into a complex human immune system without the risk of a graft-
versus-host reaction (GVHR), since thymus education of human T-cells occurs in the context of mouse 
MHC molecules [99]. In immunocompromised mice, HSCs differentiate into helper T-cells, cytotoxic 
T-cells, B cells, monocytes, NK cells and DCs [100]. To date, the use of PDX models with HSC-
reconstructed immune systems is the most common way to evaluate the treatment with anti-PD-1 
and anti-CTLA4 antibodies [101,102]. For example, in the model of humanized cord blood (CB)-HSC 
mice, nivolumab (anti-PD-1 antibody) inhibited the growth of MDA-MB-231 triple negative breast 
cancer and CRC172 colorectal cancer cells, stimulating an antitumor T-cell response by the increase 
in the number of granzyme B (GrB) or interferon (IFN)-γ CD8+ T-cells in the tumors [102]. However, 
the use of allogeneic CD34+ HSCs in the same model can give different results. For example, it was 
shown that the therapy with pembrolizumab (anti-PD-1 antibody) both suppressed and did not affect 
the growth of bladder cancer and non-small-cell lung carcinoma (NSCLC) in NSG mice with the 
immune system reconstructed with HSCs from different donors. However, the authors did not find 
any connection between the effectiveness of the therapy with the level of mismatch of human 
leukocyte antigen (HLA) class I and II or with the number PD-1+ leukocytes. In addition, the 
evaluation of therapy effectiveness can be complicated by the fact that due to the partial mismatch of 
HLA between the tumor and immune cells, human T-cells can inhibit tumor growth regardless of 
therapy [101]. NSG mice transplanted with human CD34+ cells can be used to evaluate the toxicity of 
CAR T-cells against HSCs. For example, the use of CAR T-cells targeted at the CD44v6 adhesion 
receptor prevented the engraftment of acute myeloid leukemia and multiple human myeloma in the 
CD34+ humanized mice. The only side effect was transient monocytopenia, which cleared up after a 
decrease in the number of CAR T-cells [103]. 
The main difficulty PDX models may face in the context of immunotherapy adjustments for 
patients is the time it takes to produce the in vivo tumor model. For a reasonable time, it is necessary 
to successfully transplant a tumor into several animals, as well as reconstruct the patient’s 
hematopoietic system [104]. In order to quickly restore the autologous human immune system in 
immunocompromised mice with the patient’s tumors, PBMCs from adult donors can be used, since 
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it is not necessary to wait for the formation of differentiated cells from HSCs up to 10–14 weeks 
[105,106]. PBMCs are also much easier to collect from patients and their engraftment time is reduced 
to four weeks [106]. However, the lifespan of PBMCs in PDX animals is much shorter compared to 
HSCs, so the time to evaluate immunotherapy is reduced to 4–8 weeks (Figure 1D) [86]. In addition, 
the administrated PBMCs generate stable GVHR [107]. In order to support the engraftment of 
transplanted cells, animals expressing proteins of the human immune system have been developed 
on the basis of NSG mouse models [98]. For example, NSG-SGM3 mice express human IL3, 
granulocyte macrophage colony stimulating factor (GM-CSF), and stem cell factor (SCF), which 
allows stable engraftment of human HSCs. This model promotes long-term engraftment with 
expanding populations of T-cells (CD4+, CD8+ and regulatory T-cells (Tregs)), B cells and myeloid 
cells [108]. Another MISTRG mouse model supports the engraftment and development of innate 
immune system cells, in particular myeloid cell, through the production of human signal regulatory 
protein α (SIRPα), macrophage colony-stimulating factor (M-CSF), IL3, GM-CSF and 
thyroperoxidase (TPO) [109,110]. The antitumor activity of nivolumab, atezolizumab (anti-PD-L1 
antibody), pembrolizumab and other ICIs has been evaluated on PBMC-humanized mouse models 
[106,111]. In mice with gastric carcinoma and PBMCs from the same patient, co-administration of 
urelumab (human IgG4 monoclonal antibody, which targets 4-1BB) and nivolumab was sufficient to 
significantly slow tumor growth [111]. One study has indicated that a lung cancer model based on 
PBMCs and xenograft cell line derived from the same donor was more accurate when evaluating PD-
L1/PD-1 immunotherapy, compared to an HSC-based model of the same tumor [106]. 
In highly immunocompromised mice, individual immune cell populations can also be restored. 
Functional human NK cells, Tregs and γδT-cells can be restored in immunodeficient animals and 
used to evaluate the antitumor effects of these cells or their effects on immunotherapy [112–114]. The 
use of mouse models with a partially restored immune system allows for evaluation of the effect of 
CAR T-cells on other components of the human immune system [114,115]. In one study, renal cell 
carcinoma and NK cell-transplanted NSG mice were treated with carbonic anhydrase IX (CAIX)-
targeted CAR T-cells that secrete anti-PD-L1 antibodies. The secreted antibodies were able to recruit 
human NK cells to the tumor site by binding to the Fcγ receptor on the NK cell surface [115]. In the 
nude mouse model, it was demonstrated that CAR T-cells with CD28 co-stimulatory domain were 
ineffective against solid CEA+ tumors due to the high Treg tumor infiltration associated with the 
presence of the CD28 domain [114]. 
Comparative characteristics of various mouse tumor models are represented in Table 1. 
Table 1. Comparative characteristics of mouse tumor models. 
Tumor Model 
The Origin of 
the Tumor 
Heterogeneity of 
the Tumor 
Сomplexity 
of the 
Production 
Сomplexity of the 
Microenvironment 
Сomplexity 
of the 
Immune 
System 
Price 
Syngenic tumor 
models 
Transplanted 
mouse tumor 
cells 
Low 
Easy to set 
up, rapid 
tumor 
development 
Tumor does not 
form a natural 
microenvironment 
Fully 
functional 
mouse 
immune 
system 
Low 
in 
cost 
Genetically 
engineered models 
De novo 
formed tumor 
induced by 
introduced 
mutations 
Higher than in 
syngeneic 
models, depends 
on the 
production 
method 
Difficult to 
set up, time-
consuming  
The tumor forms a 
natural 
microenvironment 
Fully 
functional 
mouse 
immune 
system 
High 
in 
cost 
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Carcinogen-induced 
tumor models 
De novo 
formed tumor 
induced by 
carcinogens 
High 
Difficult to 
set up, time-
consuming 
The tumor forms a 
natural 
microenvironment 
Fully 
functional 
mouse 
immune 
system 
High 
in 
cost 
PDX 
models 
HSC-
humanized 
Patient-
derived 
tumor 
High 
Difficult to 
set up, 10–12 
weeks are 
required for 
HSC 
engraftment 
TME is partially 
transplanted from 
the patient, but its 
complexity 
depends on the 
place of 
transplantation 
and the donor of 
the immune cells 
The 
complex 
human 
immune 
system, no 
GVHR 
High 
in 
cost 
PBMC-
humanized 
Patient-
derived 
tumor 
High 
Difficult to 
set up, short 
time 
engraftment 
The 
complex 
human 
immune 
system, 
induce 
GVHR 
High 
in 
cost 
6. Conclusions 
Mice are good models for evaluating the effectiveness of immunotherapeutic agents because 
these laboratory animals are easy to maintain, relatively cheap, have a short lifespan, and short 
reproductive cycle. Syngeneic tumor models make it possible to create an in vivo model of a tumor 
by transplanting mouse tumor cell lines into immunocompetent animals in a short period of time. 
Such models are used for investigating the interaction of the tumor and the immune system, however, 
they do not reflect all the difficulties of both the tumor itself and its microenvironment. The rapid 
kinetics of tumor growth in syngeneic models often provides an inadequate time interval for 
evaluating the effectiveness of immunotherapy. In addition, to study the effectiveness of CAR T-cell 
therapy in syngeneic models, CAR T-cells have to be derived from murine cells, and the encouraging 
results of such studies often fail to repeat in clinical trials. Therefore, they cannot provide adequate 
models for the study of immunotherapeutic drugs for the treatment of human cancer. 
Tumor GEMMs provide more opportunities for testing new immunotherapeutic agents due to 
de novo tumor formation and better TME modeling. The sequential development of the tumor allows 
the formation of more complex TME and provides a more complex interaction with the immune 
system, since the tumor passes through all stages of immunosurveillance. GEMMs are very important 
for investigating the undesirable side effects associated with CAR T-cell therapy, as this tumor model 
can be modified to express human TAAs, which are expressed not only in tumors, but also at lower 
levels in healthy tissues. However, since the creation of GEEMs is a very time-consuming and 
expensive process, and again the evaluation of immunotherapy in mouse tumors with TME 
represented by mouse cells yields mixed results, the use of these models to evaluate CAR T-cell and 
ICI immunotherapy is limited. 
CI mouse models are usually not used to evaluate the effectiveness of CAR T-cell therapy or ICIs 
due to the fact that in such animals it is difficult to control and evaluate the immune response due to 
the large number of unknown neoantigens. 
Transplantation of human tumor cell lines or primary tumors into immunocompromised mice 
allows the creation of human xenograft models, which are the most used method for the study of 
CAR T-cell therapy and ICIs. The reconstruction of the human immune system in xenograft models 
allows investigating aspects of human biology, such as the effect of various cytokines or other 
populations of human immune cells on the effectiveness of immunotherapy. The human immune 
system in animals can be reconstructed using CD34+ HSCs or PBMCs, which makes it possible to 
obtain the most accurate PDX models in which the tumor and immune components are obtained 
from the same donor. The development of this direction looks most promising, since such models 
can allow immunotherapy adjustments for a particular patient. These models may more accurately 
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reflect a patient’s immune responses compared to current models with partial HLA matching. 
However, human bone marrow-derived stem cells have a limited ability to develop into immune 
cells in humanized mice, and PBMCs have limited engraftment possibilities. Therefore, mouse 
models that support the engraftment and development of human immune cells in humanized mice 
due to the secretion of cytokines and growth factors that do not cross-react between the mouse and 
human have been created. Improving these models will allow the formation of the fully functional 
human immune system in xenograft models and provide a significant tool for assessing the 
effectiveness of cancer immunotherapy. 
Thus, today we have at our disposal mouse models, none of which can reflect all aspects of the 
complex genetics and biology of human cancer. Understanding the advantages and disadvantages of 
each model will ensure the most efficient use of the systems available today in order to facilitate the 
development of immunotherapeutic drugs and enhance continued evaluation of their effectiveness. 
At the same time, the development of new mouse models reflecting the interaction of the tumor and 
TME in as much detail as possible will increase the efficiency of translation of encouraging results of 
immunotherapy from bench to clinic. 
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